Maurits Geerlings | President & CEO
NanoCell Therapeutics

Maurits Geerlings, President & CEO, NanoCell Therapeutics

https://nanocelltx.com/about-us/

Appearances:



Advanced Therapies USA 2025 - Day 1 @ 14:35

Non-viral delivery of stably integrating DNA for in vivo CAR-T TCR therapy

Maurits Geerlings, President & CEO, NanoCell Therapeutics

Advanced Therapies USA 2025 - Day 1 @ 17:10

Panel Discussion: In vivo gene editing of immune cells - opportunities, challenges & alternative approaches

Moderator: David Peritt, Chief Scientific Officer, Lupagen
Cecile Bauche, Chief Scientific Officer, Alaya.bio
Maurits Geerlings, President & CEO, NanoCell Therapeutics
Devyn Smith, CEO, Arbor Biotechnologies
Minghong Zhong, CEO, GeneLancet Biosciences, Inc.
Guobao Chen, Principal Research Scientist, AbbVie
Daniel Dornbusch, CEO, Excision Biotherapeutics
Yu (Clay) Cao, Vice President, Global Head of Drug Discovery, GenEditBio Limited

Advanced Therapies USA 2025 - Day 2 @ 14:05

Panel Discussion: Ex vivo vs In vivo cell engineering

Moderator: Rafal P. Witek, VP, Translational R&D, Head of Liver Program, Dimension Bio
Raisa Uchurova, Scientist, Century Therapeutics
Maurits Geerlings, President & CEO, NanoCell Therapeutics
Holger Russ, Associate Professor, University of Florida
Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
Christopher Murriel, Vice President, Pre-Clinical Pharmacology, ArsenalBio
Daniel Baker, PhD Candidate, June Lab, University of Pennsylvania School Of Medicine
Parimal Pande, Associate Scientific Director, Johnson & Johnson
last published: 30/Jun/25 16:05 GMT

back to speakers

Get Involved with the Advanced Therapies Congress

 

To sponsor or exhibit


Natasha Bangle
natasha.bangle@terrapinn.com
+44 20 3545 5515


Joshua Lloyd
Josh.Lloyd@terrapinn.com
+44 20 4614 9423

 

To speak


Chris Shanks
chris.shanks@terrapinn.com
+44 20 8152 7604